<- Go Home
TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
Market Cap
$286.3K
Volume
144.0K
Cash and Equivalents
$1.0M
EBITDA
-$11.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$109.87
52 Week Low
$0.44
Dividend
N/A
Price / Book Value
0.13
Price / Earnings
-0.01
Price / Tangible Book Value
0.19
Enterprise Value
$935.4K
Enterprise Value / EBITDA
-0.08
Operating Income
-$11.9M
Return on Equity
577.04%
Return on Assets
-98.20
Cash and Short Term Investments
$1.0M
Debt
$1.7M
Equity
$2.0M
Revenue
N/A
Unlevered FCF
-$6.7M
Sector
Biotechnology
Category
N/A